Biofrontera Inc. Files 2024 10-K

Ticker: BFRIW · Form: 10-K · Filed: Mar 20, 2025 · CIK: 1858685

Sentiment: neutral

Topics: 10-K, annual-report, pharmaceuticals

Related Tickers: BFRI

TL;DR

Biofrontera filed its 2024 10-K. All the deets on financials and risks are in there.

AI Summary

Biofrontera Inc. filed its 2024 10-K on March 20, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The filing details its business operations, financial condition, and risk factors. Key financial data and disclosures regarding its common stock, warrants, and various series of preferred stock are included, along with information on related and non-related parties.

Why It Matters

This 10-K filing provides investors and stakeholders with a comprehensive overview of Biofrontera's financial health and strategic positioning for the past fiscal year, crucial for investment decisions.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Biofrontera faces inherent risks related to drug development, regulatory approvals, market competition, and intellectual property.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of Biofrontera Inc.?

Biofrontera Inc. is primarily involved in the pharmaceutical preparations industry, as indicated by its SIC code 2834.

When did Biofrontera Inc. file its 10-K report?

Biofrontera Inc. filed its 10-K report on March 20, 2025.

What fiscal year does this 10-K report cover?

This 10-K report covers the fiscal year ending December 31, 2024.

What is the state of incorporation for Biofrontera Inc.?

Biofrontera Inc. is incorporated in Delaware (DE).

What is the business address of Biofrontera Inc.?

The business address for Biofrontera Inc. is 120 Presidential Way, Suite 330, Woburn, MA 01801.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on March 20, 2025 regarding Biofrontera Inc. (BFRIW).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing